ATLANTIS: A Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line

Anna F. Farago, Benjamin J. Drapkin, Jose Antonio Lopez-Vilarino De Ramos, Carlos M. Galmarini, Rafael Núñez, Carmen Kahatt, Luis Paz-Ares

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Lurbinectedin is an inhibitor of active transcription of protein-coding genes, causing DNA-break accumulation, apoptosis and modulation of the tumor microenvironment. Early-phase clinical trials indicate promising activity of lurbinectedin in small-cell lung cancer. Here, we describe the rationale and design of ATLANTIS (NCT02566993), an open-label, randomized, multicenter Phase III study to compare the efficacy of lurbinectedin and doxorubicin combination with standard-of-care chemotherapy, investigator's choice of cyclophosphamide/doxorubicin/vincristine or topotecan, in patients with small-cell lung cancer that has progressed following one line of platinum-based chemotherapy. Patients are randomized in a 1:1 ratio. The primary end point is overall survival and key secondary end points include progression-free survival, best tumor response and duration of response, each assessed by independent review committee.

Original languageEnglish (US)
Pages (from-to)231-239
Number of pages9
JournalFuture Oncology
Volume15
Issue number3
DOIs
StatePublished - Jan 2019
Externally publishedYes

Keywords

  • lurbinectedin
  • Phase III trial
  • small-cell lung cancer
  • targeting transcription

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'ATLANTIS: A Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line'. Together they form a unique fingerprint.

  • Cite this